SIRTUIN 5 POLYMORPHISMS AND NEUROLOGICAL DISEASES
A method for determining a subject's risk of developing a neurological disease or disorder such as Huntington's or Parkinson's disease, based on the presence of SIRT5 prom2 (rs9382222) C/C genotype is provided. Also provided are compositions including primers and probes, which are capable of selectively interacting with nucleic acids, such as those comprising the SNP disclosed herein.
1 . A method for determining a subject's risk or propensity of developing a neurological disease or disorder, comprising:
determining the SIRT5 prom2 (rs9382222) genotype in a sample obtained from the subject, wherein the presence of the SIRT5 prom2 (rs9382222) C/C genotype is indicative of an increased risk of developing a neurological disease or disorder relative to a subject with an SIRT5 prom2 (rs9382222) C/T genotype.
2 . The method of claim 1 wherein the neurological disease or disorder is related to mitochondrial dysfunction.
3 . The method of claim 1 wherein the neurological disease or disorder is Huntington's disease.
4 . The method of claim 1 wherein the neurological disease or disorder is Parkinson's disease.
5 . The method of claim 1 wherein the neurological disease or disorder is schizophrenia.
6 . The method of claim 1 , wherein the SIRT5 prom2 (rs9382222) genotype is detected by gene sequencing.
7 . The method of claim 1 , wherein the SIRT5 prom2 (rs9382222) genotype is detected by allele specific hybridization.
8 . The method of claim 1 , wherein a treatment protocol is selected for the subject based on the presence of the SIRT5 prom2 (rs9382222) C/C genotype.
9 . A method for determining a subject's risk or propensity of developing a neurological disease or disorder, comprising:
determining the SIRT5 prom2 (rs9382222) genotype in a sample obtained from the subject, wherein the presence of SIRT5 prom2 (rs9382222) C/T genotype is indicative of a reduced risk of developing a neurological disease or disorder relative to a subject with an SIRT5 prom2 (rs9382222) C/C genotype.
10 . The method of claim 9 wherein the neurological disease or disorder is Huntington's disease.
11 . The method of claim 9 wherein the neurological disease or disorder is Parkinson's disease.
12 . The method of claim 9 wherein the neurological disease or disorder is Alzheimer's disease.
13 . The method of claim 9 wherein the neurological disease or disorder is selected from the group consisting of schizophrenia, bipolar disorder, and amyotrophic lateral schlerosis.
14 . A nucleic acid probe comprising at least 14 nucleotides that specifically hybridizes under stringent conditions to an SIRT5 prom2 (rs9382222) C allele or T allele.
15 . The nucleic acid probe of claim 14 , wherein the nucleic acid probe is a molecular beacon.
16 . The nucleic acid probe of claim 14 , wherein the nucleic acid probe is attached to a solid support.
17 . The nucleic acid probe of claim 14 , wherein the nucleic acid probe is a component of a kit.
18 . The nucleic acid probe of claim 14 , wherein the nucleic acid probe is labeled with a detectable label.
19 . The nucleic acid probe of claim 14 wherein the nucleic acid probe consists of 14-20 consecutive nucleotides of SEQ ID NO:1 spanning the cystidine at position 27 of SEQ ID NO:1, or a complement thereof, wherein the nucleic acid probe specifically hybridizes to SEQ ID NO:1 under stringent conditions.
20 . The nucleic acid probe of claim 14 wherein the nucleic acid probe consists of 14-20 consecutive nucleotides of SEQ ID NO:2 spanning the thymidine at position 27 of SEQ ID NO:2, or a complement thereof, wherein the nucleic acid probe specifically hybridizes to SEQ ID NO:2 under stringent conditions.